Spectrum Medical marketed Quantum perfusion devices beyond cleared uses and had corrective-action failures.
What happened
FDA inspected Spectrum Medical Ltd’s Gloucester, United Kingdom, facility on April 24, 2023 through April 27, 2023 and reviewed U.S. promotional material and user manuals collected during the inspection. FDA found several Quantum Perfusion devices marketed for uses beyond their cleared indications, including extracorporeal life support (ECLS), intensive care unit (ICU) use, and patient transport, and found corrective and preventive action (CAPA) deficiencies under the Quality System regulation. The company’s May 5, 2023 response did not adequately address the violations.
What FDA found
FDA found the Quantum PureFlow Centrifugal Pumps marketed for 29-day use and for ECLS, ICU, and transport use, although they are cleared only for cardiopulmonary bypass in open surgery for up to 6 hours.
21 CFR 807.81(a)(3)(ii); FD&C Act sections 501(f)(1)(B), 502(o), and 510(k)FDA found the Quantum Roller Pumps and Quantum Power Supply Lite listed and promoted as part of an ECLS system for ICU and transport use, beyond their cleared use in cardiopulmonary bypass for up to 6 hours.
21 CFR 807.81(a)(3)(ii); FD&C Act sections 501(f)(1)(B), 502(o), and 510(k)FDA found the Quantum SuperPAC cannulas and tubing set promoted for ECLS, ICU, and transport use without the cleared 6-hour limit or CPB-only use.
21 CFR 807.81(a)(3)(ii); FD&C Act sections 501(f)(1)(B), 502(o), and 510(k)FDA found the Quantum Ventilation Module Lite and Charlotte frame configuration marketed for ICU, transport, or ECLS uses that were not in the cleared submissions.
21 CFR 807.81(a)(3)(ii); FD&C Act sections 501(f)(1)(B), 502(o), and 510(k)CAPA 342 did not identify actions to correct nonconforming product already in the field or consider risks and preventive actions for a slipping or failure-to-lock issue.
21 CFR 820.100(a)(3)CAPA 315 lacked verification or validation that a packaging change for a leaking heat transfer fluid bag was effective and did not adversely affect the finished device.
21 CFR 820.100(a)(4)
What FDA wants
Within 15 business days of receiving the letter, Spectrum Medical must notify FDA in writing of the steps taken to correct the violations, prevent recurrence, and include documentation and a timetable for any longer-term actions. If corrections cannot be completed in that time, the company must state why and when they will be completed.
Who should pay attention
- hospitals and clinicians using Quantum perfusion or life-support devices
- U.S. distributors and brands carrying Spectrum Medical devices
- quality and regulatory teams handling 510(k) labeling changes or CAPA effectiveness
This is a summary. Read the original letter on fda.gov.